2011
Pharmacotherapy for Primary CNS Lymphoma
Graber JJ, Omuro A. Pharmacotherapy for Primary CNS Lymphoma. CNS Drugs 2011, 25: 447-457. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaCNS lymphomaHigh-dose methotrexate-based chemotherapyMore effective chemotherapy regimensRefractory primary CNS lymphomaEffective chemotherapy regimensOptimal chemotherapy combinationReduced-dose radiotherapySingle-agent methotrexateMethotrexate-based chemotherapyStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyLong-term remissionProgression-free survivalOngoing clinical trialsCombination of drugsChemotherapy regimensChemotherapy combinationsChemotherapy optionsRadiotherapy resultsSerious complicationsClinical trialsCell rescueConsolidation treatment
2010
Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
Omuro A, Taillandier L, Chinot O, Sierra del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K, On behalf of the ANOCEF Group (French Neuro-Oncology Association).. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? Journal Of Neuro-Oncology 2010, 104: 323-330. PMID: 21170569, DOI: 10.1007/s11060-010-0497-x.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyHigh-dose chemotherapyProgression-free survivalPrimary central nervous system lymphomaSalvage whole brain radiotherapyComplete responseOverall survivalNeurotoxicity riskMedian progression-free survivalCentral nervous system lymphomaAdditional chemotherapy cyclesEffective salvage treatmentMedian overall survivalStem cell rescuePrimary CNS lymphomaNervous system lymphomaObjective of treatmentChemosensitive diseaseChemosensitive patientsChemotherapy cyclesInduction chemotherapyBrain radiotherapyCNS lymphomaObjective responseSalvage treatment
2007
Editorial: what is new in the treatment of gliomas?
Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-707. PMID: 17992093, DOI: 10.1097/wco.0b013e3282f1beef.Peer-Reviewed Original ResearchConceptsTreatment of gliomaTherapeutic decisionsEvidence-based therapeutic decisionsBevacizumab-based combinationsRecurrent malignant gliomaRole of chemotherapyPhase II trialStandard of carePhase III evidenceHigh response ratePhase II resultsSingle positive resultTemozolomide concomitantTemozolomide schedulesII trialSurvival benefitRandomized trialsGrade IIIMalignant gliomasResponse rateGliomasSuch trialsTraditional treatmentTrialsCodeletion status